To compare efficacy and safety of oral contraceptive pill vs pioglitazone in polycystic ovary syndrome (PCOS) women.
Phase 4
- Conditions
- Health Condition 1: E282- Polycystic ovarian syndrome
- Registration Number
- CTRI/2020/03/024267
- Lead Sponsor
- SKIMS
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- ot Yet Recruiting
- Sex
- Not specified
- Target Recruitment
- 0
Inclusion Criteria
1.Age group 15-40 years.
2.Drug Naïve patients or no hormone therapy in past 6 months.
3.Who are ready to avoid any other medication during trial and 6 months after it.
4.Who are ready to give consent for participation in trial.
Exclusion Criteria
1.History of thromboembolic events
2. pregnancy
3. Breast feeding females
4.Females who are planning to conceive
5.Idiopathic hyperandrogenism
6. Non classical hyperandrogenism
7.Cushing syndrome and androgen secreting tumors
8.Patient on current hormonal therapy
9.Thyroid dysfunction
10.Liverdisease
10.
Study & Design
- Study Type
- Interventional
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method FG score, serum testosterone, IS (HOMA, MATSUDA, QUICKI, WBISI), Glucose toleranceTimepoint: 0 months, 3 months, 6 months
- Secondary Outcome Measures
Name Time Method Menstrual cyclicity, BMI, Waist circumference(WC), acne, inflammatory markers (CRP, IL6 and TNF alpha).Timepoint: o months, 3 months, 6 months